<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Growth failure in children with chronic kidney disease: Prevention and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Growth failure in children with chronic kidney disease: Prevention and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Growth failure in children with chronic kidney disease: Prevention and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Burkhard Tönshoff, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H359700116"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Growth failure is a major complication of children with chronic kidney disease (CKD). Poor growth is a marker of disease severity and is associated with significant morbidity and mortality [<a href="#rid1">1,2</a>].</p><p>The prevention and management of growth failure in children with CKD and after kidney transplantation will be reviewed here. The impact, risk factors, evaluation, and diagnosis of growth failure in children with CKD are discussed separately. (See  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H359700212"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H359700220"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>Classification schema for CKD in children is based upon the level of kidney function (defined by glomerular filtration rate [GFR]) as follows  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>G1 – Normal GFR (≥90 mL/min per 1.73 m<sup>2</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span>G2 – GFR between 60 and 89 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3a – GFR between 45 and 59 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3b – GFR between 30 and 44 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G4 – GFR between 15 and 29 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G5 – GFR of less than 15 mL/min per 1.73 m<sup>2</sup> (kidney failure)</p><p></p><p class="headingAnchor" id="H359700228"><span class="h2">Growth measurement</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Z-score</strong> (also called standard deviation score [SDS]) for height (or length) represents the number of standard deviations (SD) from the mean height values for age. (See  <a class="medical medical_review" href="/d/html/5356.html" rel="external">"Measurement of growth in children", section on 'Use of Z-scores'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth velocity</strong> (or height velocity) is the change in growth over time. It is a more sensitive index of growth compared with a single measurement. It is determined by comparing current height/length measurements with previous growth points  (<a class="graphic graphic_figure graphicRef96367" href="/d/graphic/96367.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef96366" href="/d/graphic/96366.html" rel="external">figure 2</a>).</p><p></p><p class="headingAnchor" id="H359697767"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The prevention and management of growth impairment in children with CKD are based on addressing the following factors that contribute to poor growth (see  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis", section on 'Contributing factors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate nutrition</p><p class="bulletIndent1"><span class="glyph">●</span>Fluid and electrolyte abnormalities including metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Renal osteodystrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Disturbances of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis</p><p></p><p>The management approach consists of a combination of the following interventions:</p><p class="bulletIndent1"><span class="glyph">●</span>Supportive measures are directed toward preventing or correcting amenable complications of CKD, including malnutrition, metabolic acidosis, fluid and electrolyte abnormalities, and renal osteodystrophy. (See <a class="local">'Supportive measures'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney replacement therapy (KRT; ie, dialysis and/or kidney transplantation) is generally initiated in children with stage 5 CKD and who have uremic symptoms and/or metabolic abnormalities that are refractory to medical management. KRT facilitates fluid management and ensures adequate nutrition. Kidney transplantation is the optimal KRT modality to prevent and correct growth failure. (See  <a class="medical medical_review" href="/d/html/16179.html" rel="external">"Overview of kidney replacement therapy for children with chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Growth after kidney transplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children requiring immunosuppression for management of kidney disease (eg, nephrotic syndrome, post-transplant), glucocorticoid-sparing agents are used when possible since glucocorticoid therapy is a major contributor to poor growth. (See <a class="local">'Reducing glucocorticoid exposure'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13354" href="/d/drug information/13354.html" rel="external">Recombinant human growth hormone</a> (rhGH) therapy to address GH/IGF-1 abnormalities. (See  <a class="medical medical_review" href="/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone"</a>.)</p><p></p><p class="headingAnchor" id="H359697775"><span class="h1">SUPPORTIVE MEASURES</span><span class="headingEndMark"> — </span>Supportive care should be provided to all children with CKD. This includes correcting and preventing any of the amenable contributing factors for growth failure.</p><p class="headingAnchor" id="H359700278"><span class="h2">Nutrition</span><span class="headingEndMark"> — </span>Early referral to a pediatric nephrology center followed by careful nutritional and metabolic management is vital in the prevention of growth retardation. Sufficient nutritional support including energy and protein intake is essential for normal growth, particularly for infants in whom growth is most sensitive to energy intake. Successful nutritional management requires a multidisciplinary team that includes clinicians, skilled nurses, and dieticians.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Energy requirements</strong> – Energy intake should be 100 percent of the Dietary Reference Intake (DRI) based on age and sex  (<a class="graphic graphic_table graphicRef56276" href="/d/graphic/56276.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein requirements</strong> – Protein intake depends on the stage of CKD:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with stages 3a and 3b CKD, protein intake should be between 100 to 140 percent of DRI based on age and sex  (<a class="graphic graphic_table graphicRef81506" href="/d/graphic/81506.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with CKD stages 4 and 5 CKD, protein intake should be between 100 and 120 percent of DRI based upon age and sex (<a class="graphic graphic_table graphicRef81506" href="/d/graphic/81506.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children undergoing chronic peritoneal dialysis (CPD), protein intake should be increased to compensate for protein losses in the dialysate. The aim is to maintain a normal serum albumin and a urea &lt;20 mmol/L, if possible. </p><p></p><p>For children with polyuric salt-wasting CKD who are unable to adequately concentrate their urine or conserve salt, supplementation with formulas containing additional sodium at high volumes appears to improve growth [<a href="#rid4">4</a>]. </p><p>Enteral feeding is indicated in children with CKD when spontaneous calorie intake is insufficient to maintain growth. Routes for enteral feeding include gastrostomy and nasogastric tubes. In an observational study of 153 young children (less than 24 months) who commenced peritoneal dialysis (PD), gastrostomy feeding compared with either nasogastric tube feeding or demand feeding was associated with improved linear growth [<a href="#rid5">5</a>]. This finding may be due to decreased episodes of vomiting associated with gastrostomies compared with nasogastric tubes.</p><p>With early initiation of intensive nutritional and medical care including enteral feedings, severe growth failure in infants with CKD can be prevented with catch-up growth [<a href="#rid5">5,6</a>]. In a study from a single center of 101 infants with CKD, intensive nutrition (approximately 90 percent were fed enterally) and early kidney transplantation resulted in a mean normal adult height in patients without comorbidities [<a href="#rid6">6</a>].</p><p>However, even optimal nutritional management may not be able to prevent growth failure in many patients, particularly older children with advanced stages of CKD. Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) database showed that catch-up growth without <a class="drug drug_pediatric" data-topicid="13354" href="/d/drug information/13354.html" rel="external">recombinant human growth hormone</a> (rhGH) therapy was only observed in children &lt;5 years old [<a href="#rid7">7</a>]. These results demonstrate that other factors such as disturbances of growth hormone (GH) metabolism and its primary mediator, insulin-like growth hormone-1 (GH/IGF-1 axis), are important contributors to impaired growth in children with CKD, which optimal nutrition alone cannot overcome. As a result, rhGH therapy has been a beneficial intervention in these patients. (See  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis", section on 'Pathogenesis: Disturbance of growth hormone/IGF-1 axis'</a> and  <a class="medical medical_review" href="/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone", section on 'Efficacy'</a>.)</p><p class="headingAnchor" id="H80286581"><span class="h2">Other supportive measures</span><span class="headingEndMark"> — </span>Other supportive measures include preventing or correcting the following risk factors that contribute to growth impairment in children with CKD :</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic acidosis – Prevention and correction of metabolic acidosis with administration of oral bicarbonate preparations. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Metabolic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrolyte and fluid loss – Replacement of increased kidney losses of fluids and electrolytes. Supplementation of sodium chloride is important in young children on PD, since significant amounts of sodium chloride (ie, 2 to 5 mmol/kg of body weight) may be lost via ultrafiltration of the peritoneal fluid. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Fluid and electrolyte abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal osteodystrophy – Monitoring mineral and bone status with routine measurements of serum calcium, phosphate, parathyroid hormone (PTH) levels, and, if appropriate, 25-hydroxyvitamin D levels. Interventions are initiated depending on laboratory results and include phosphate restriction, calcium and vitamin D supplementation, and the use of phosphate binders. (See  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia – Anemia is corrected with the administration of erythropoiesis stimulating agents (eg, recombinant human erythropoietin and its longer-acting analog <a class="drug drug_pediatric" data-topicid="13206" href="/d/drug information/13206.html" rel="external">darbepoetin</a>). (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Erythropoiesis-stimulating agents'</a>.)</p><p></p><p>However, apart from nutritional support in early infancy, true catch-up growth can rarely be obtained by any of these therapeutic interventions. At most, a growth pattern parallel to the growth percentiles is observed in response to optimization of nutritional support and medical treatment in children with CKD beyond infancy.</p><p class="headingAnchor" id="H11199014"><span class="h1">KIDNEY REPLACEMENT THERAPY (KRT)</span><span class="headingEndMark"> — </span>Once children have reached end-stage kidney disease (ESKD; ie, stage 5 CKD), growth rates generally continue to deteriorate. In particular, patients who receive chronic dialysis are at risk for growth failure. Although dialysis attenuates the uremic state, longitudinal growth is not usually improved and long-term peritoneal dialysis (PD) or hemodialysis are associated with a gradual loss of standardized height in children and adolescents, which can be a loss of one standard deviation (SD) of height per year in infants [<a href="#rid8">8,9</a>]. Children on dialysis who maintain some residual kidney function have the best growth; indeed, residual kidney function may be a better predictor of longitudinal growth than dialytic clearance [<a href="#rid10">10,11</a>]. Even children who undergo kidney transplantation and theoretically should have normal growth, and potentially catch-up growth in prepubertal patients, still are at risk for growth impairment, particularly as a result of glucocorticoid therapy. (See  <a class="medical medical_review" href="/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature", section on 'Is the child short?'</a>.)</p><p class="headingAnchor" id="H359697782"><span class="h2">Hemodialysis</span><span class="headingEndMark"> — </span>Children who undergo long-term conventional hemodialysis (ie, three treatments per week) generally have further deterioration of their growth  (<a class="graphic graphic_figure graphicRef83843" href="/d/graphic/83843.html" rel="external">figure 3</a>) [<a href="#rid12">12</a>]. This was illustrated by one case series of 51 children who underwent conventional hemodialysis for 12 to 111 months that reported a 0.4 SD annual loss of mean relative height [<a href="#rid13">13</a>]. In this study, one-third of the patients grew along the growth percentile attained at initiation of dialysis, one-third had slightly retarded growth, and one-third had severely retarded growth.</p><p>With increased intensity of nutrition and hemodialysis (eg, hemodiafiltration six times per week or nocturnal hemodialysis), single-center studies have reported that the growth rate of children on maintenance hemodialysis improved significantly [<a href="#rid14">14,15</a>]. In an observational study comparing outcomes on conventional hemodialysis (HD) versus postdilution hemodiafiltration (HDF) in children, height SD score slightly increased in HDF but remained static in HD [<a href="#rid16">16</a>]. A possible mechanism behind this finding is that intensified dialysis improves clearance of solutes, middle molecules, and inflammatory cytokines, and reverses the abnormalities of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis secondary to CKD. (See  <a class="medical medical_review" href="/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Type, length, and frequency of dialysis sessions'</a> and  <a class="medical medical_review" href="/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Growth'</a>.)</p><p class="headingAnchor" id="H359697789"><span class="h2">Continuous peritoneal dialysis</span><span class="headingEndMark"> — </span>Growth appears to be better after the start of continuous peritoneal dialysis (PD) in children, especially in those below six years of age after conservative treatment or compared with hemodialysis  (<a class="graphic graphic_figure graphicRef83844" href="/d/graphic/83844.html" rel="external">figure 4</a>) [<a href="#rid12">12,17</a>]. This relative improvement in growth compared with hemodialysis has been partially attributed to the better nutritional status of patients as a consequence of their peritoneal glucose uptake [<a href="#rid18">18</a>]. PD is usually more effective in solute and fluid removal than conventional hemodialysis, and improved growth and nutritional status are correlated with increased solute and volume clearance [<a href="#rid18">18</a>]. However, a gradual decline of relative height is frequently observed in children who have undergone long-term PD, indicating that the impact of the dialysis modality on growth diminishes with time [<a href="#rid19">19,20</a>]. These data temper the initial enthusiasm that PD would result in a significant beneficial sustained impact on growth. At best, parallel growth along the child's growth percentile is achieved by PD, but not persistent catch-up growth. (See  <a class="medical medical_review" href="/d/html/16400.html" rel="external">"Chronic peritoneal dialysis in children"</a>.)</p><p class="headingAnchor" id="H359697796"><span class="h2">Transplantation</span><span class="headingEndMark"> — </span>Kidney transplantation is the optimal KRT modality to prevent and correct growth failure, as a well-functioning allograft restores the physiological conditions required for normal growth. However, growth rates after kidney transplantation in children are highly variable and often do not fulfill the expectations of true catch-up growth, which generally is only observed in children less than five years of age [<a href="#rid21">21</a>]. The main contributing factors to continued growth depression in pediatric kidney allograft recipients are glucocorticoid treatment for immunosuppression, reduced graft function and administration of growth hormone pretransplantation [<a href="#rid22">22</a>]. The final height also depends on the age of the child and the severity of the growth failure at time of transplantation  (<a class="graphic graphic_figure graphicRef83842" href="/d/graphic/83842.html" rel="external">figure 5</a>). (See  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Growth after kidney transplantation'</a>.)</p><p class="headingAnchor" id="H359697803"><span class="h1">REDUCING GLUCOCORTICOID EXPOSURE</span><span class="headingEndMark"> — </span>Daily glucocorticoid therapy following kidney transplantation or to treat glomerular disease has historically been an important contributor to poor growth in children. Strategies to reduce the cumulative effects of glucocorticoid therapy include late or early glucocorticoid withdrawal and use of alternative immunosuppressive agents.</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney transplant – The introduction of other immunosuppressive agents, particularly calcineurin inhibitors (ie, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> and <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>) and the antimetabolite, <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil (MMF), has greatly reduced the need for glucocorticoid therapy in pediatric kidney transplant recipients. Clinical trials and observational studies have demonstrated that steroid-sparing regimens are associated with improved growth following transplantation [<a href="#rid23">23</a>]. Additional details of glucocorticoid-sparing immunosuppressive regimens post-transplant are provided separately. (See  <a class="medical medical_review" href="/d/html/6128.html" rel="external">"Kidney transplantation in children: Immunosuppression", section on 'Glucocorticoid-sparing regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotic syndrome – The use of glucocorticoid-sparing therapy in children with nephrotic syndrome is discussed separately. (See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Alternative treatments for patients with steroid toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H12337646"><span class="h1">RECOMBINANT HUMAN GROWTH HORMONE THERAPY</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13354" href="/d/drug information/13354.html" rel="external">Recombinant human growth hormone</a> (rhGH) therapy is safe and effective in improving growth in children with CKD, including allograft recipients. The European Society for Paediatric Nephrology (ESPN) CKD-Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups developed clinical practice recommendations for the use of rhGH in children with CKD on dialysis and after kidney transplantation [<a href="#rid24">24</a>]. The indications, dosing, efficacy, and side effects of rhGH are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone"</a>.)</p><p class="headingAnchor" id="H434022009"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110751.html" rel="external">"Society guideline links: Chronic kidney disease in children"</a>.)</p><p class="headingAnchor" id="H359697838"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance</strong> – Growth retardation is a major complication of children with chronic kidney disease (CKD). Poor growth is a marker of disease severity and is associated with significant morbidity and mortality. (See  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis", section on 'Impact of poor growth'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Supportive care for children with CKD aims to correct and prevent amenable contributing factors for growth impairment. This includes (see <a class="local">'Supportive measures'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Optimal nutrition</strong> – Nutritional support focuses on ensuring adequate energy and protein intake  (<a class="graphic graphic_table graphicRef56276" href="/d/graphic/56276.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef81506" href="/d/graphic/81506.html" rel="external">table 3</a>). If spontaneous calorie intake is insufficient to maintain growth, initiation of enteral feeding via gastrostomy or nasogastric tube may be required. (See <a class="local">'Nutrition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other supportive measures</strong> – Interventions for other complications of CKD include the following, each of which is discussed separately (see <a class="local">'Other supportive measures'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Bicarbonate therapy to treat metabolic acidosis (see  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Metabolic acidosis'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Correction of electrolyte and fluid abnormalities (see  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Fluid and electrolyte abnormalities'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Vitamin D and calcium supplementation and phosphate restriction to treat renal osteodystrophy (see  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Management'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Erythropoiesis stimulating agents for anemia (see  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Erythropoiesis-stimulating agents'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney replacement therapy (KRT)</strong> – Once children have reached end-stage kidney disease (ESKD, stage 5 CKD), growth rates generally deteriorate. Kidney replacement therapy (KRT; ie, dialysis and/or kidney transplantation) is generally initiated in children with ESKD and those who have uremic symptoms and/or metabolic abnormalities that are refractory to medical management. Kidney transplantation is the optimal KRT modality to prevent and correct growth failure. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16179.html" rel="external">"Overview of kidney replacement therapy for children with chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Growth after kidney transplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reducing glucocorticoid exposure</strong> – Glucocorticoid therapy following kidney transplantation or to treat glomerular disease has historically been an important contributor to poor growth in children with CKD. The introduction of other immunosuppressive agents (eg, calcineurin inhibitors [<a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>, <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>]) and <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil [MMF]), has greatly reduced the need for glucocorticoid therapy in pediatric kidney transplant recipients. Details regarding use of glucocorticoid-sparing immunosuppressive therapy in kidney transplant recipients and in children with nephrotic syndrome are provided separately. (See  <a class="medical medical_review" href="/d/html/6128.html" rel="external">"Kidney transplantation in children: Immunosuppression", section on 'Glucocorticoid-sparing regimen'</a> and  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Alternative treatments for patients with steroid toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13354" href="/d/drug information/13354.html" rel="external">Recombinant human growth hormone</a><strong> (RhGH)</strong> – RhGH is a safe therapeutic intervention that promotes growth in children with CKD, including in those who are pediatric kidney allograft recipients. Use of RhGH in children with CKD is discussed separately. (See  <a class="medical medical_review" href="/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mahan JD, Warady BA, Consensus Committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 2006; 21:917.</a></li><li><a class="nounderline abstract_t">André JL, Bourquard R, Guillemin F, et al. Final height in children with chronic renal failure who have not received growth hormone. Pediatr Nephrol 2003; 18:685.</a></li><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">Parekh RS, Flynn JT, Smoyer WE, et al. Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy. J Am Soc Nephrol 2001; 12:2418.</a></li><li><a class="nounderline abstract_t">Rees L, Azocar M, Borzych D, et al. Growth in very young children undergoing chronic peritoneal dialysis. J Am Soc Nephrol 2011; 22:2303.</a></li><li><a class="nounderline abstract_t">Mekahli D, Shaw V, Ledermann SE, Rees L. Long-term outcome of infants with severe chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:10.</a></li><li><a class="nounderline abstract_t">Seikaly MG, Salhab N, Gipson D, et al. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol 2006; 21:793.</a></li><li><a class="nounderline abstract_t">Neu AM, Bedinger M, Fivush BA, et al. Growth in adolescent hemodialysis patients: data from the Centers for Medicare &amp; Medicaid Services ESRD Clinical Performance Measures Project. Pediatr Nephrol 2005; 20:1156.</a></li><li><a class="nounderline abstract_t">Quinlan C, Bates M, Sheils A, et al. Chronic hemodialysis in children weighing less than 10 kg. Pediatr Nephrol 2013; 28:803.</a></li><li><a class="nounderline abstract_t">Shroff R, Wright E, Ledermann S, et al. Chronic hemodialysis in infants and children under 2 years of age. Pediatr Nephrol 2003; 18:378.</a></li><li><a class="nounderline abstract_t">Chadha V, Blowey DL, Warady BA. Is growth a valid outcome measure of dialysis clearance in children undergoing peritoneal dialysis? Perit Dial Int 2001; 21 Suppl 3:S179.</a></li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual dialysis report. https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.</li><li><a class="nounderline abstract_t">Kleinknecht C, Broyer M, Gagnadoux MF, et al. Growth in children treated with long-term dialysis. A study of 76 patients. Adv Nephrol Necker Hosp 1980; 9:133.</a></li><li><a class="nounderline abstract_t">Fischbach M, Terzic J, Menouer S, et al. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol Dial Transplant 2010; 25:867.</a></li><li><a class="nounderline abstract_t">Hoppe A, von Puttkamer C, Linke U, et al. A hospital-based intermittent nocturnal hemodialysis program for children and adolescents. J Pediatr 2011; 158:95.</a></li><li><a class="nounderline abstract_t">Shroff R, Smith C, Ranchin B, et al. Effects of Hemodiafiltration versus Conventional Hemodialysis in Children with ESKD: The HDF, Heart and Height Study. J Am Soc Nephrol 2019; 30:678.</a></li><li><a class="nounderline abstract_t">Stefanidis CJ, Hewitt IK, Balfe JW. Growth in children receiving continuous ambulatory peritoneal dialysis. J Pediatr 1983; 102:681.</a></li><li><a class="nounderline abstract_t">Schaefer F, Klaus G, Mehls O. Peritoneal transport properties and dialysis dose affect growth and nutritional status in children on chronic peritoneal dialysis. Mid-European Pediatric Peritoneal Dialysis Study Group. J Am Soc Nephrol 1999; 10:1786.</a></li><li><a class="nounderline abstract_t">Fine RN, Salusky IB. CAPD/CCPD in children: four years' experience. Kidney Int Suppl 1986; 19:S7.</a></li><li class="breakAll">International Pediatric Peritoneal Dialysis Network. About IPPN [online] http://www.pedpd.org/index.php?id=98 (Accessed on May 09, 2011).</li><li><a class="nounderline abstract_t">Tejani A, Fine R, Alexander S, et al. Factors predictive of sustained growth in children after renal transplantation. The North American Pediatric Renal Transplant Cooperative Study. J Pediatr 1993; 122:397.</a></li><li><a class="nounderline abstract_t">Grohs J, Rebling RM, Froede K, et al. Determinants of growth after kidney transplantation in prepubertal children. Pediatr Nephrol 2021; 36:1871.</a></li><li><a class="nounderline abstract_t">Tsampalieros A, Knoll GA, Molnar AO, et al. Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis. Transplantation 2017; 101:694.</a></li><li><a class="nounderline abstract_t">Drube J, Wan M, Bonthuis M, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 2019; 15:577.</a></li></ol></div><div id="topicVersionRevision">Topic 83284 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16773402" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12750982" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Final height in children with chronic renal failure who have not received growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675418" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021715" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Growth in very young children undergoing chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965538" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term outcome of infants with severe chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16583244" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Stature in children with chronic kidney disease: analysis of NAPRTCS database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15977027" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Growth in adolescent hemodialysis patients: data from the Centers for Medicare&amp;Medicaid Services ESRD Clinical Performance Measures Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23263665" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic hemodialysis in children weighing less than 10 kg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700966" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chronic hemodialysis in infants and children under 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11887816" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Is growth a valid outcome measure of dialysis clearance in children undergoing peritoneal dialysis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11887816" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Is growth a valid outcome measure of dialysis clearance in children undergoing peritoneal dialysis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6250378" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Growth in children treated with long-term dialysis. A study of 76 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889872" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691454" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A hospital-based intermittent nocturnal hemodialysis program for children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846560" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of Hemodiafiltration versus Conventional Hemodialysis in Children with ESKD: The HDF, Heart and Height Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6341531" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Growth in children receiving continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10446947" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Peritoneal transport properties and dialysis dose affect growth and nutritional status in children on chronic peritoneal dialysis. Mid-European Pediatric Peritoneal Dialysis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3462425" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : CAPD/CCPD in children: four years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3462425" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : CAPD/CCPD in children: four years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441094" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Factors predictive of sustained growth in children after renal transplantation. The North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33620573" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Determinants of growth after kidney transplantation in prepubertal children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27736823" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31197263" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
